Nurix Therapeutics, Inc. 4

Chief Legal Officer Christine Ring exercised 5,787 Nurix Therapeutics stock options at $8.72 and sold 16,589 common shares at an average of $23.0489 on August 3, 2026, ending with 9,110 shares owned.

On August 3, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 5,787 stock options at an exercise price of $8.72 per share, acquiring 5,787 shares of common stock and increasing her direct holdings to 25,699 shares before any sale. On the same date, pursuant to a Rule 10b5-1 trading plan, she sold 16,589 shares of Nurix common stock at a weighted average price of $23.0489 per share (within a range of $22.67 to $23.30), leaving her with 9,110 shares owned directly after the sale. The option exercise appears to relate to an employee stock option that vests monthly from March 13, 2024 through February 13, 2027, and the net effect of the transactions was a reduction in her directly held common stock despite the option exercise.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817199-26-000028

Alert Tier

6